Previous 10 | Next 10 |
Ligand Pharmaceuticals (NASDAQ: LGND ) acquired two privately held companies that strengthen and complement its OmniAb ® technology platform. More news on: Ligand Pharmaceuticals Incorporated, Merger & acquisition news, Healthcare stocks news, Read more ...
The acquired technologies continue to position Ligand’s OmniAb as a best-in-class platform for antibody discovery Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb ® te...
There are a number of reasons why you might be interested in the future sales/revenue growth of a company. For instance, in order to perform a discounted cash flow analysis of a stock, it's one of the essential inputs. Or perhaps, you believe that the higher a company's projected sales growth,...
Merger activity increased last week with four new deals announced and two deals completed. M&A activity continues to pick up pace as we come close to the end of the third quarter. We had been tracking two of the four new deals announced last week in our "Deals in the Works" table before ...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at an upcoming investor conference. Management will deliver a company presentation for the H.C. Wainwright 22 nd annual global investment virtual conference on Monday, September 14 ...
IMVT-1401 is a novel anti-FcRn OmniAb-derived antibody delivered by subcutaneous injection Registration-enabling Phase 3 trial expected to initiate in the first half of 2021 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, Inc. (NASDAQ: IMV...
KYPROLIS is an Amgen product that utilizes Captisol ® in its formulation Approval based on the CANDOR and EQUULEUS Studies Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug A...
Merger activity increased significantly last week with eight new deals announced and one deal terminated. This is the highest number of deals announced in a single week this year but most of these deals were relatively small compared to the multi-billion-dollar deals we saw in the week prior...
Ligand Pharmaceuticals ( LGND ) is a company with an interesting business model, one which I have provided coverage on at various occasions in the past. The last update on the company and the investment thesis dates March 2019 as I concluded that uncertainty prevails. This uncertainty ca...
Ligand reports planned acquisition of Pfenex Ligand Pharmaceuticals Inc. ( LGND ) announced that it has inked a definitive agreement with Pfenex Inc. ( PFNX ) for acquiring the latter. The companies expect the transaction to be closed in the fourth quarter of 2020, subject to required re...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-08-02 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...